Tranexamic acid, administered orally or topically, reduces hyperpigmentation in melasma by inhibiting melanogenesis and blocking keratinocyte-melanocyte interaction. This leads to a visible reduction in melasma.
Oral and topical tranexamic acid can reduce hyperpigmentation in melasma by inhibiting melanogenesis induced by UV exposure. This inhibition is thought to occur by blocking the interaction between keratinocytes and melanocytes, ultimately leading to a reduction in the appearance of melasma.
No ingredients yet
Ingredients that provide this benefit will appear here.